Roche ended 2020 on a disappointing note, with biosimilar erosion and pandemic disruption taking their toll on the lynchpin Pharmaceuticals division. Although some meaningful support, as expected, surfaced from Diagnostics – a major pandemic beneficiary. While the near term remains uncertain, there’s apt balance-sheet strength to pass this phase with minimal negative implications for growth plans and shareholder rewards. And, on top, with the innovations under-development, Roche remains amongst ....